After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...